About InnerPath

 

InnerPath’s treatment programs are designed to provide a personalized psychedelic-assisted therapeutic experience that meets our clients individual goals, from reducing symptoms of anxiety, depression, PTSD to improving substance misuse disorders, interpersonal conflict resolution and physical ailment concerns.

Our treatment centres are intentionally created to offer cutting-edge clinical support with a variety of psychoactive substances, offering a completely unique opportunity to research psychedelics through survey, observation and direct clinical trial support in a regulated environment.


 

InnerPath Wellness is a psychedelic therapeutics company improving how mental health disorders are treated.  Our integrative approach innovates upon years of psychedelic, psychiatric and psychopharmacological research, study and application; and is vested in centuries of traditional medicine and community care models. 

 

Our Team

Mark Goliger, CEO, President, & Board Member

  • President of GoodCap Pharmaceuticals, a life sciences company developing psilocybin-based therapeutics.

  • CEO of META Growth (TSXV: META), acquired by High Tide for $50M.

  • COO of Qualicare and Right at Home Canada

Irie Selkirk, Chief Operating Officer

  • Founder and Director of Rise Wellness, the world’s first low-dose psilocybin retreat, acquired for $1M.

  • Co-founder of Sansero Life Sciences, acquired for $7M. 

  • VP GoodCap Pharmaceuticals. 

  • MAPS Canada Toronto Support Chapter Co-Founder.

Robin Banister, Lead Therapist

  • Working as a psychedelic-assisted psychotherapist for over 5 years and prior to that had her own private practice.

  • Trained by MAPS and Fluence

  • Worked at Rise Wellness Retreats which was the world's first low-dose psilocybin retreat.

  • Two years working at Field Trip Health which was Canada's first ketamine-assisted psychotherapy clinic.

 

Michael Haines,

Board Member

  • Co-Founder and Chairman of Hoshi International, a European regulated cannabis producer with facilities in Malta and Portugal.

  • Co-founder and Director of Mettrum Health Corp. Acquired by Canopy Growth for $430M.

Trevor Fencott,

Chairman

  • Co-founder and CEO of Fire & Flower (TSX: FAF).

  • Co-founder and Director of Mettrum Health Corp. Acquired by Canopy Growth for $430M.

  • Co-founder and Director of PopReach Incorporated (TSXV: POPR).